Friday, June 19, 2020 2:40:37 PM
That doesn't prevent us from posting what we know, or learn here, but it explains why the company won't go on the record and promote all who're distributing their product either using the PCTL labeled product, or packaging it themselves.
I would suspect that nearly all distributors who don't produce the HOCL themselves order it in bulk and repackage it. I would think they'd have the option of using their own label, or PCTL's label.
Even if the website can't clearly show all that's going on, over time the earnings will clearly show the growth in the company. It may take a little longer waiting for earnings, but they're coming and by this time next year I believe it's very possible that we'll move the decimal point two places to the right.
We have a number of people here, like Egold, who're excellent at identifying distributors who're using our products, but doing so in their own names. I suspect that in the future it's very possible that a market, drugstore, etc might have more than one product on the shelf that's HOCL being provided by different distributors under different labels that's all being produced with PCTL's process, in some cases it may have been produced by PCTL, whereas in other the distributor may be producing it on equipment from the company. Regardless of how or where it's produced, somehow the company gets paid.
Gary
Recent PCTL News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 02:05:09 PM
- Form 15-12G/A - Securities registration termination [Section 12(g)]: [Amend] • Edgar (US Regulatory) • 07/18/2023 07:06:52 PM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/13/2023 04:32:57 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM